Efficacy of Infliximab as 'Bridging Therapy' in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine.

Trial Profile

Efficacy of Infliximab as 'Bridging Therapy' in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Infliximab (Primary) ; Azathioprine; Prednisolone
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 02 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top